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ABSTRACT
Introduction: The study objective was to
evaluate the intraocular pressure (IOP) and
medication-lowering effect of 2
second-generation trabecular micro-bypass
stents in eyes with open-angle glaucoma
(OAG) on one preoperative medication.
Methods: Fifty-seven qualified phakic eyes with
OAG on 1 medication, preoperative medicated
IOP of 18–30 mmHg, and preoperative
unmedicated (post-washout) IOP of
22–38 mmHg underwent implantation of
2 second-generation trabecular micro-bypass
stents in a standalone procedure. Evaluations
included IOP, best-corrected visual acuity,
medication use, fundus and slit lamp
examinations, visual field, cup to disc ratio,
pachymetry, and complications and
interventions. Subjects have been followed for
18 months, and follow-up is ongoing.
Results: AtMonth12postoperative, 100%of eyes
had achieved an IOP reduction C20% (100% had
IOP B18 mmHg and 67% had IOP B15 mmHg)
without medication versus preoperative
unmedicated IOP, and 75% had IOP reduction
C20% without medication versus preoperative
medicated IOP. The Month 12 mean
unmedicated IOP had decreased by 42%, to
14.2± 1.9 mmHg vs 24.4± 1.3 mmHg
preoperatively, and this reduction was
maintained through 18 months (14.4±
2.1 mmHg). A high safety profile was observed.
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Conclusion: In this prospective, open-label,
single-arm study, the standalone implantation
of two second-generation trabecular
micro-bypass stents in OAG patients on 1
preoperative medication resulted in IOP
reduction to B15 mmHg and elimination of
medication through 18 months, with favorable
safety.
Trial Registration: ClinicalTrials.gov identifier,
NCT02868190.
Funding: Glaukos Corporation, San Clemente,
CA.
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INTRODUCTION
The most important risk factor for glaucoma,
the leading cause of permanent blindness
worldwide [1], is elevated intraocular pressure
(IOP). Thus, a central goal of all glaucoma
therapy is IOP reduction, which can be
achieved through pharmacologic, laser, or
surgical means. Traditionally, trabeculectomy
has been considered the gold standard of
glaucoma surgery, but typically it has been
reserved for more advanced stages of the
disease [2]. Over the past decade, the
development of microinvasive glaucoma
surgery (MIGS) procedures has increased the
surgical options available to clinicians treating
mild to moderate open-angle glaucoma (OAG).
The first FDA-approved MIGS device, the
first-generation iStent (iStent Trabecular
Micro-Bypass, Glaukos Corporation, San
Clemente, CA, USA), is a single-piece titanium
stent designed to bypass the main site of
aqueous fluid outflow resistance in OAG, the
trabecular meshwork, with minimal trauma to
intraocular and extraocular structures. A
substantial body of literature has shown that
ab interno implantation of these stents can
reduce IOP and medication burden for up to 5
years postoperatively in patients with mild to
moderate OAG. Key studies have evaluated
outcomes after implantation of single [3–6]
and multiple [7] iStent devices during cataract
surgery, and with multiple iStent devices as a
standalone procedure [8–11].
More recent years have brought the advent
of second-generation trabecular micro-bypass
stents (iStent inject Trabecular Micro-Bypass,
Glaukos Corporation, San Clemente, CA, USA).
Several studies have demonstrated substantial
IOP and medication reduction following
implantation of 2 iStent inject devices during
cataract surgery [12] or in standalone
procedures [13–16]. In addition to their
clinical effectiveness, these devices have
shown a favorable safety profile, which is an
important advantage over traditional surgeries
such as trabeculectomy or tube placement, or
more recently developed suprachoroidal stents
[17, 18].
In the present study, we tested the
hypothesis that IOP and medication burden
would be reduced following the standalone
implantation of 2 second-generation iStent
inject devices in eyes with OAG not controlled
on 1 preoperative medication, while
maintaining favorable safety parameters. This
report covers outcomes in 57 eyes through
18 months postoperation, and follow-up is
continuing through 5 years.
METHODS
This was a prospective, unmasked, single-arm
study designed to enroll phakic or
pseudophakic (with posterior chamber
intraocular lens) subjects with OAG, medicated
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IOP at screening of 18–30 mmHg on 1 topical
ocular hypotensive medication, and
unmedicated (post-washout) IOP of
22–38 mmHg. Medication washout included
5 days for carbonic anhydrase inhibitors,
2 weeks for alpha agonists, and 4 weeks for
beta blockers and prostaglandin analogues.
Subjects were to have cup to disc (C:D) ratio of
B0.9, best-corrected visual acuity (BCVA) of
20/100 or better, and normal angle anatomy.
Exclusion criteria included pseudoexfoliative,
pigmentary, uveitic, traumatic, neovascular, or
angle-closure glaucoma; glaucoma associated
with vascular disorders; and prior glaucoma
surgery of any kind.
This single-site study was conducted at the
S.V. Malayan Ophthalmological Center in
Yerevan, Armenia. All surgeries were
performed by the staff surgeon (L. Voskanyan)
and 10 visiting surgeons from the MIGS Study
Group (Supplementary Material—Appendix 1).
Pre- and postoperative examinations were
completed by glaucoma-trained
ophthalmologists at the Center. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients for being included in
the study. The ClinicalTrials.gov registration
number for this study is NCT02868190.
As described previously in detail [12–15], the
second-generation iStent inject device is a
single-piece, titanium, heparin-coated stent
with 360 lm length, 230 lm maximum width,
and multiple lateral outlet lumens to facilitate
aqueous fluid outflow (Fig. 1). Two stents are
pre-loaded in a single disposable stainless steel
inserter, which is advanced ab internally
through a temporal clear corneal incision to
implant 2 stents through the trabecular
meshwork into the nasal Schlemm’s canal at
approximately 2 clock-hours apart. The
bypassing of the trabecular meshwork is
designed to promote aqueous outflow and
thereby decrease IOP. Using this technique, all
subjects had implantation of 2 iStent inject
devices in the nasal Schlemm’s canal at
approximately 2 clock-hours apart.
Postoperatively, patients received topical
anti-infective medication (for 1 week) and
anti-inflammatory medication (for 4 weeks).
Efficacy and safety evaluations included IOP
measurement (Goldmann applanation
tonometry), BCVA (Early Treatment Diabetic
Retinopathy Study scale), slit lamp
biomicroscopy, indirect ophthalmoscopy, C:D
ratio, visual field (Swedish Interactive
Thresholding Algorithm Standard 24-2
automated perimetry), pachymetry,
medication use, and ocular complications and
secondary surgical interventions. Postoperative
examinations occurred at Day 1; Week 1;
Fig. 1 The iStent inject and iStent inject trabecular micro-bypass stent system
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Months 1, 3, 6, and 12; and are planned for
every 6 months, thereafter until Month 60.
Additional ocular hypotensive medication was
to be started if postoperative IOP exceeded
21 mmHg at any postoperative visit, and/or in
the case of concerning optic nerve findings, at
the discretion of the investigator.
The primary efficacy endpoint was the
proportion of patients with a Month 12 mean
unmedicated IOP reduced by C20% versus
baseline unmedicated IOP. The secondary
efficacy endpoints included the proportion of
patientswithMonth12 IOPofB18orB15 mmHg
without medications; and the proportion of
patients with Month 12 IOP reduced by C20%
without medication versus baseline medicated
IOP. Proportional analyseswereperformed for the
primary and secondary efficacy endpoints. For
continuous variables, mean and standard
deviation values were calculated. Statistical tests
were performed using software from the R Project





A total of 57 qualified subjects underwent ab
interno implantation of 2 iStent inject devices in
a standalone procedure (i.e., without cataract
surgery). Table 1 shows demographic and
preoperative parameters. Mean age was
65.3 ± 9.0 years, with approximately equal
gender distribution. All subjects were phakic.
Preoperative mean medicated IOP was
19.5 ± 1.5 mmHg on 1 medication, and mean
unmedicated (post-washout) IOP was
24.4 ± 1.3 mmHg. Subjects have been followed
for 18 months, and follow-up is ongoing.
Efficacy
Figure 2 shows a proportional analysis of IOP at
Month 12, and Fig. 3 shows the mean IOP over
time for the 18-month period after stent
implantation (N = 57). At Month 12, 100% of
eyes had achieved an IOP reduction C20%
(100% had IOP B18 mmHg and 67% had IOP
B15 mmHg) without medication versus
preoperative unmedicated IOP, and 75% had
IOP reduction C20% versus preoperative
medicated IOP. At Month 18, mean
unmedicated IOP had decreased 41% versus
preoperative unmedicated IOP (to
Table 1 Subject demographic and preoperative
characteristics (N = 57)





Caucasian 100% (n = 57)
Age (years)
Mean ± SD 65.3 ± 9.0
Preoperative cup-to-disc (C:D) ratio
mean ± SD
0.7 ± 0.1




Mean ± SD 1 ± 0
Type of medications
Prostaglandin 86% (n = 49)
Beta-blocker 7% (n = 4)
Carbonic anhydrase inhibitor 7% (n = 4)
Preoperative unmedicated IOP
(mmHg) mean ± SD
24.4 ± 1.3
IOP intraocular pressure, SD standard deviation
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14.4 ± 2.1 mmHg from 24.4 ± 1.3 mmHg
preoperatively); and had decreased 27% versus
preoperative medicated IOP (19.5 ± 1.5
preoperatively). One subject was placed on a
medication at Month 18 for optic nerve
findings (IOP was 17.7 mmHg), but all
remaining subjects remained off medications.
Safety
All subjects underwent uncomplicated ab
interno placement of 2 iStent inject devices in a
standalone procedure, with no intraoperative
adverse events observed. Postoperatively, 1
subject had progression of preexisting cataract
with corresponding BCVA loss [1 line. BCVA
has been stable over time for the remaining
subjects (93% with Month 18 BCVA 20/40 or
better and 98% with BCVA 20/100 or better)
(Fig. 4). The mean C:D ratio, visual field mean
deviation and pattern standard deviation, and
central corneal thickness also remained
stable over the 18-month follow-up (Table 2).
DISCUSSION
Data from this prospective study confirm the
hypothesis that phakic subjects with OAG and
on 1 ocular hypotensive medication can
successfully and safely achieve sustained IOP
and medication reduction following
implantation of two second-generation iStent
inject devices as a sole procedure. Specifically, a
C20% IOP reduction with elimination of
medication was achieved in all subjects at
12 months, with all patients maintaining IOP
of B18 mmHg and two-thirds reaching IOP of
B15 mmHg. At Month 12, the mean
unmedicated IOP had decreased by 42%, to
14.2 vs 24.4 mmHg preoperatively, and this
reduction was maintained through 18 months
(14.4 mmHg).
These outcomes corroborate the
considerable existing body of research showing
substantial IOP and medication reduction and
favorable safety of ab interno trabecular
micro-bypass implantation in patients with
mild to moderate glaucoma. Prior studies have
evaluated single [3–6] and multiple [7]
first-generation stents (iStent) during cataract
surgery; multiple first-generation stents as a
standalone procedure [8–11]; and two
second-generation stents (iStent inject) either
with [12] or without cataract surgery in OAG
Fig. 2 Proportional analysis of Month 12 intraocular
pressure (IOP) (N = 57). M month
Fig. 3 Mean intraocular pressure (IOP) over time
(N = 57). BL baseline, M month, PRE preoperative
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patients with moderate IOP elevation and/or
medication burden [13–16]. In the present
study, the observed IOP reduction of
10.2 mmHg was similar to the 7.0–10.5 mmHg
reduction observed in these earlier studies of
standalone iStent inject implantation in phakic
eyes with OAG [13–16]. The present study
analyzes IOP and medication use after
standalone iStent inject implantation in phakic
OAG eyes with IOP not managed to below
18 mmHg on 1 preoperative medication. Thus,
the findings shed light on the utility of these
stents in a relatively early stage of managing the
disease.
The reduction in medication-free IOP
supports the independent effect of
second-generation trabecular micro-bypass
stents without the confounding factors of
concomitant cataract surgery or medication
use. Perhaps even more meaningful, subjects’
postoperative IOP was 27% lower without
medications 18 months after receiving 2 iStent
inject devices than with medication before
surgery. The elimination of medication
represents a benefit in terms of both cost [19]
and compliance [20–23] to glaucoma patients,
most of whom have at least one other chronic
condition demanding their funds and attention
[24]. Indeed, an inherent advantage of ab interno
trabecular bypass stents over medications is
reduced dependence on medication
compliance, which theoretically may increase
long-term treatment success.
Safety outcomes were favorable through the
18 months of follow-up, with only 1
postoperative adverse event (BCVA loss due to
cataract progression; cataract surgery has been
planned) and no intraoperative or
device-related adverse events. Furthermore, the
study’s involvement of multiple surgeons offers
external validation of safety of the implantation
technique. This favorable safety profile is
consistent with that observed in previous
studies of iStent inject in subjects with mild to
moderate primary OAG [12–16]. One additional
medication was started in 1 eye at 18 months
(IOP was 17.7 mmHg), but all remaining eyes
remained medication-free, and no eyes
underwent secondary surgery. Subject
accountability was 100% through 18 months,
supporting the validity of the study’s findings.
Fig. 4 Preoperative and Month 18 best-corrected visual
acuity (BCVA) (N = 57). M month, PRE preoperative
Table 2 Screening and postoperative mean cup-to-disc (C:D) ratio, visual ﬁeld (VF), and central corneal thickness, available
eyes at each visit
Screening M6 M12 M18
N 57 57 57 57
C:D ratio mean (SD) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1)
VF—mean deviation (dB) mean (SD) -4.9 (5.3) -4.8 (5.3) -4.5 (5.1) -4.5 (5.2)
VF—pattern standard deviation (dB) mean (SD) 3.3 (2.4) 3.1 (2.3) 3.1 (2.3) 3.0 (2.3)
Corneal thickness (lm) mean (SD) 544.9 (30.3) 546.1 (30.0) 545.6 (29.9) 545.4 (29.7)
M month, SD standard deviation
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This is a nonrandomized, open-label,
single-arm study with several limitations
which may be noted. The study’s single-site
design prevents a consideration of site-specific
effects or measurement variability as potential
confounders. Since multiple IOP readings were
not taken, regression to the mean is a
possibility. Because stent implantation was
completed as a standalone procedure in this
study, a sham surgical control group (consisting
of merely injecting and removing viscoelastic)
was not considered for ethical reasons.
However, we considered it reasonable that
patients’ preoperative data served as their own
control. The patient population was 100%
Caucasian and included only phakic eyes,
making it impossible to stratify by race or lens
status. IOP measurements at multiple time
points were not taken for every visit, diurnal
IOP was not measured, and standardized
preoperative grading of the crystalline lens was
not completed.
CONCLUSIONS
This study collected valuable data in a
stable cohort with excellent accountability
through 18 months, and follow-up is ongoing.
The results confirm that IOP reduction to
B15 mmHg with elimination of medication—
and a favorable safety profile—is possible after
the standalone implantation of two iStent inject
devices in OAG eyes with IOP not managed to
below 18 mmHg on 1 preoperative medication.
In light of this positive benefit-to-risk profile, as
well as the well-known issues with compliance,
cost, and side effects associated with topical
medications, this microsurgical technique may
constitute a desirable alternative for these
patients with earlier stages of OAG.
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